This ruling has zero material impact on JNJ's operations, cash flows, or legal exposure. Xarelto product liability litigation has been ongoing for years with thousands of federal cases previously resolved or managed through MDL 2592. A single plaintiff's pro se dismissal on procedural grounds is not a read-through for broader Xarelto liability. No trader response warranted.
Price Chart
Executive Summary
The Ninth Circuit affirmed the district court's dismissal of a product liability case against Janssen (JNJ subsidiary) and Bayer over Xarelto. The ruling was on procedural grounds — a child cannot bring loss-of-parental-consortium claims under California law, and a non-attorney guardian cannot prosecute pro se. The case was dismissed with no damages, no injunction, and no liability finding against JNJ. This is a complete win for JNJ on a routine, immaterial matter.
Court Ruling Details
Key Facts
- Ninth Circuit affirmed dismissal of Hu v. Janssen over Xarelto injury claims
- Loss of consortium claim dismissed with prejudice under California law (Borer v. American Airlines)
- Remaining claims dismissed without prejudice because plaintiff, as non-attorney guardian, cannot litigate pro se
- No damages, no injunction, no liability finding against Janssen or Bayer
- Case is a routine procedural win for JNJ — no material financial exposure
Financial Impact
None — no damages awarded, no liability found, no ongoing exposure. Case was dismissed entirely on procedural grounds.
Risk Factors
- Xarelto litigation broadly has been materially resolved — no systemic risk from this case
- No appeal possible on the loss-of-consortium claim (affirmed); other claims dismissed without prejudice but plaintiff lacks counsel to refile
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-tus9vruz-JNJ |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Court Ruling | $267.08 $267.28 | ▲ +0.07% | ▲ +0.73% | $258.14 (−3.35%) |
Aug 18, 2026 6w ago | Insider Cluster | $273.41 $270.00 | ▼ −1.25% | ▼ −0.86% | $258.14 (−5.58%) |
Aug 14, 2026 7w ago | Insider Cluster | $260.35 $270.24 | ▲ +3.80% | ▲ +5.17% | $258.14 (−0.85%) |
Aug 7, 2026 7w ago | Insider Cluster | $261.81 $262.37 | ▲ +0.21% | ▲ +0.26% | $258.14 (−1.40%) |
Aug 7, 2026 8w ago | Court Ruling | $259.24 $260.35 | ▼ −0.43% | ▼ −0.03% | $258.14 (+0.42%) |
Aug 4, 2026 8w ago | 8-K | $254.93 $259.80 | ▲ +1.91% | ▲ +2.01% | $258.14 (+1.26%) |
Jul 22, 2026 10w ago | Court Ruling | $255.63 $265.53 | ▼ −3.87% | ▼ −6.27% | $258.14 (−0.98%) |
Jul 15, 2026 11w ago | 8-K | $247.02 $255.63 | ▲ +3.49% | ▲ +4.47% | $258.14 (+4.50%) |
May 20, 2026 19w ago | Court Ruling | $229.12 $231.29 | ▲ +0.95% | ▼ −0.29% | $258.14 (+12.67%) |
May 13, 2026 20w ago | ANALYST-UPGRADE | $230.79 $231.58 | ▲ +0.34% | ▲ +1.06% | $258.14 (+11.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access